143 related articles for article (PubMed ID: 20586973)
21. Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration.
Ren XS; Crivera C; Sikirica M; Dirani R; Qian S; Kazis LE
J Clin Pharm Ther; 2011 Jun; 36(3):383-9. PubMed ID: 21062329
[TBL] [Abstract][Full Text] [Related]
22. Explicit review of risperidone long-acting injection prescribing practice.
Wheeler A; Vanderpyl J; Carswell C; Stojkovic M; Robinson E
J Clin Pharm Ther; 2011 Dec; 36(6):651-63. PubMed ID: 22023342
[TBL] [Abstract][Full Text] [Related]
23. Health resource utilization associated with switching to risperidone long-acting injection.
Young CL; Taylor DM
Acta Psychiatr Scand; 2006 Jul; 114(1):14-20. PubMed ID: 16774656
[TBL] [Abstract][Full Text] [Related]
24. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
[TBL] [Abstract][Full Text] [Related]
25. Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia.
Arunpongpaisal S; Srisurapanont M; Kongsakon R; Kitiwattanagul K; Samanwongthai U
J Med Assoc Thai; 2010 Mar; 93(3):343-50. PubMed ID: 20420110
[TBL] [Abstract][Full Text] [Related]
26. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.
Mehnert A; Nicholl D; Pudas H; Martin M; McGuire A
J Med Econ; 2012; 15(5):844-61. PubMed ID: 22458756
[TBL] [Abstract][Full Text] [Related]
27. Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use.
Taylor D; Fischetti C; Sparshatt A; Thomas A; Bishara D; Cornelius V
Acta Psychiatr Scand; 2009 Aug; 120(2):97-101. PubMed ID: 19207128
[TBL] [Abstract][Full Text] [Related]
28. The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia.
Chue P; Chue J
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):259-69. PubMed ID: 22812548
[TBL] [Abstract][Full Text] [Related]
29. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
[TBL] [Abstract][Full Text] [Related]
30. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
[TBL] [Abstract][Full Text] [Related]
31. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry.
Olivares JM; Peuskens J; Pecenak J; Resseler S; Jacobs A; Akhras KS;
Curr Med Res Opin; 2009 Sep; 25(9):2197-206. PubMed ID: 19604073
[TBL] [Abstract][Full Text] [Related]
32. [Pharmacoeconomic review of the use of injectable long-acting risperidone].
Bartkó G; Fehér L
Neuropsychopharmacol Hung; 2005 Dec; 7(4):199-207. PubMed ID: 16496485
[TBL] [Abstract][Full Text] [Related]
33. Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy.
Bera R; Offord S; Zubek D; Lau G; Lin J; Karson C
J Clin Psychopharmacol; 2014 Feb; 34(1):30-5. PubMed ID: 24135840
[TBL] [Abstract][Full Text] [Related]
34. Treatment compliance in veterans administration schizophrenia spectrum patients treated with risperidone long-acting injectable.
Duncan EJ; Woolson SL; Hamer RM
Int Clin Psychopharmacol; 2012 Sep; 27(5):283-90. PubMed ID: 22644368
[TBL] [Abstract][Full Text] [Related]
35. Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands.
Pechlivanoglou P; Vehof J; van Agthoven M; de Jong-van den Berg LT; Postma MJ
Clin Ther; 2010 Jan; 32(1):108-18. PubMed ID: 20171417
[TBL] [Abstract][Full Text] [Related]
36. Comparison of treatment effectiveness and medical costs for different long-acting injectable antipsychotics in patients with schizophrenia in Taiwan: A nationwide population-based cohort study.
Wu CS; Cheng IC; Feng J; Chen CL
Schizophr Res; 2016 May; 173(1-2):37-44. PubMed ID: 26987938
[TBL] [Abstract][Full Text] [Related]
37. A comparison of the effectiveness of risperidone, haloperidol and flupentixol long-acting injections in patients with schizophrenia--A nationwide study.
Yu HY; Hsiao CY; Chen KC; Lee LT; Chang WH; Chi MH; Hui Lee I; Chen PS; Yang YK
Schizophr Res; 2015 Dec; 169(1-3):400-405. PubMed ID: 26395153
[TBL] [Abstract][Full Text] [Related]
38. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).
Olivares JM; Rodriguez-Morales A; Diels J; Povey M; Jacobs A; Zhao Z; Lam A; Villalobos Vega JC; Cuéllar JA; de Castro FJ; Quintero CM; Martíin JF; Domínguez P; Ojeda JL; Cortés SS; Cala FI; Marín CG; Castro LM; Duaso MA; Albarracín JR; Vergara GN; Benítez AF; Cleries FM; Pérez-Brian JM; Aragón AB; Navarro JC; Biedma JA; de Pedro RB; González JF; López ME; Moreno HD; López JA; Rodríguez EO; de Hoyos CM; Sacristán MP; Martín MD; Ballesteros EM; Rodríguez PA; Menéndez LF; Rivas RS; del Pino Cuadrado P; Lauffer JC; Solano JJ; Martínez JM; Solano FG; Rodríguez PG; Rodríguez JA; Cano TR; Fortacin MD; Lobeiras JM; Sampedro JM; Bravo AP; Pellicer AF; López MD; Liste JF; Fernández MR; Losada AC; Mendez RV; Romero SA; Blanco JJ; Bonaselt IT; Mahia MC; del Valle EF; Yañez PQ; Camarasa MG; Alonso JA; Mendez GF; Feliz FD; Lamela MA; Piñero MV; Alvarado PF; Gómez IL; Martín PF; Gómez JL; López AG; Jiménez AR; Nafs AE; Barquero NC; Ortiz RF; Noguera JL; Carrasco PR; Muñoz JM; Palma MM; Hortelano CM; Bonome LS; Sevilla JS; Juan JM; Ramos JM; Muñoz JL; Guisasola JE; Vazquez LS; Guerras FC; Nebot FJ; Fernández FJ; Nicolau AL; Subirats RC; Kidias MM; Navarro VF; García BF; del Rosal FM; de Vicente Muñoz T; Ballester JA; Lieb PM; Martel AD; Bea ER; Joaquim IG; Enjuanes FB; Piñol MB; Carbonell EF; Muñoz RM; Giribets CA; Sans LA; Blanco AS; Felipe MA; Muñoz PG; Villanueva AP; Arroyo MB; Borri RC; Fallada SM; Merola MC; Rodon EP; Palmes JR; Martínez EP; Catala JM; Coca AS; Ferrandiz FP; Paya EF; Caballero GI; Bonet AF; Figueras JF; Pagador PM; Garibo MM; Camo VP; Carrillo CS; Valero CP; Rebollo FJ; García Campayo J; Sala Ayma JM; Roig MM; de Uña Mateos MA; Bertolin RG; García AM; Mazo FJ; Velasco JL; Pérez LS; Casado CJ; Barba JJ; Diaz MC; Rubio JP; Mandoli AS; Herrero AU; Martínez AR; Serrano PS; Rodríguez EN; Montesinos JS; Macia JF; Mateos Marcos AM; Soto JV; Dumont MV; Pagan JP; Martínez VB; Santiuste de Pablos M; Delgado CE; Quiles MD; López FJ; Navarro PP; Torres AM; Ingles FJ; Arias-Camison JM; Manzano JC; Peña RV; Guitarte GP; Fontecilla HB; Romero JB; Gil RS; Lozano JM; Adanez LD; Zarranz Herrera-Oria I; Jiménez JP; Vaz FC; García OS; Anton CC; Casula RR; Hernandez MC; Escabias FT; Torresano JR; Pérez-Villamil AH; Estevez L; Figuero MA; Muñoz de Morales A; Calvin JL; Criado MD; Rodríguez VM; Ambrosolio EB; Madera PM; Alfaro GP; Vidal MM; Valtuille AG; Ruiz O; Cabornero GL; Echevarria Martínez de Bujo M; Mallen MJ; Puigros JS; Martorell AL; Forteza AC; Arrebola ER; Rodríguez de la Torre M; Saiz CG; Bardolet I Casas C; Linde ER; De Arce Cordon R; Molina EM; Carazo FJ; Romero JJ; Cano DV; Dorado MS; Velazquez SC; Sánchez AJ; Leon SO; Sánchez KP; Benitez MH; Zugarramurai AI; Contreras MA; De la Varga González M; Marín PB; Robina FG; García MS; Pérez FJ; Bros PC; Gómez AC; de Dios Molina Martín J; Perera JL; Averbach MC; Perera JL; Palancares EG; Gallego de Dios MT; Rojo CF; Iglesias SS; Merino MI; Mestre NP; Urdaniz AP; Sánchez JM; Seco RG; Muñoz JF; Agut MM; Lozano ML; Herguedas FM; Pena AT; García JV; Martínez AV; Sanz Granado OS; Fernández MA; Canseco JM; López PA; Martín MA; Barrio JA; Ubago JG; Bennassar MR; Díez JM; Fleta JL; Fortes FP; López CA; Medina O; Alvarez DF; Roca JM; Valladolid GR; Tavera JA; García-Castrillon Sales JA; Llordes IB; Melgarejo CA; Cañas de la Paz F; Callol VV; García MB; García JB; Leal FJ; Corrales EC; Iglesias ES; Gómez MA; Serrano GG; Chillarón EG; Aguado FJ; Castillo JJ; González AG; Vázquez JG; Peralvarez MB; Diaz MR; Mesa MY; Artiles FJ; Chao MA; Mesa MY; del Rosario Santana P; Escudero MA; Berenguer MM; Llacer JM; Berna JA; Ortiz JB; Pardell LT; Hernández-Alvarez de Sotomayor C; Méndez MR; Garate RC; Múgica BD; González MC; Domingo JP; Navarro CS; Vera GS; Cuquerella MA; Monzo JL; Boada PC; Pérez MF; Parrado EC; Sánchez JJ; Fernández JC;
Eur Psychiatry; 2009 Jun; 24(5):287-96. PubMed ID: 19195847
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China.
Yang L; Li M; Tao LB; Zhang M; Nicholl MD; Dong P
Value Health; 2009; 12 Suppl 3():S66-9. PubMed ID: 20586985
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness, Good Tolerability, and High Compliance of Doses of Risperidone Long-Acting Injectable Higher Than 75 mg in People With Severe Schizophrenia: A 3-Year Follow-Up.
Fernández-Miranda JJ; Caramés-García V; Sánchez-García A
J Clin Psychopharmacol; 2015 Dec; 35(6):630-4. PubMed ID: 26421461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
